TArgeting Type 1 Diabetes Using POLyamines (TADPOL): A Randomized, Double-Masked, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of Difluoromethylornithine (DFMO) to Preserve Insulin Production in Type 1 Diabetes
Latest Information Update: 01 Sep 2026
At a glance
- Drugs Eflornithine (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Acronyms TADPOL
Most Recent Events
- 21 Aug 2026 Planned End Date changed from 1 May 2028 to 1 Jun 2027.
- 21 Aug 2026 Planned primary completion date changed from 1 Dec 2027 to 1 Jun 2027.
- 22 Jun 2026 Status changed from recruiting to active, no longer recruiting.